Featured Clinical Study A Dose Escalation and Expansion Study of Sonodynamic Therapy With SONALA-001 in Combination With Exablate 4000 Type-2 MR-guided Focused Ultrasound in Patients With Recurrent or Progressive Glioblastoma
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study).
Despite a series of mishaps, a benefit concert for the ABTA was fated to go on. Read how organizers pulled off a successful event with brain tumor researchers taking the spotlight.
The American Brain Tumor Association (ABTA) today announced the funding of $427,000 towards 17 new 2021 research grants to improve brain tumor science and discovery. With more than $33.5 million invested in research to date, across all brain tumor types and ages, the ABTA research program plays a critical role in advancing treatments and ushering in the next generation of brain tumor researchers.
The American Brain Tumor Association (ABTA) today announced a new partnership with Brain Tumour Foundation of Canada (BTFC) to accelerate brain tumor research. Through this partnership, BTFC will invest in the ABTA research program to co-fund a research project in Canada, focused on improving resection for low-grade glioma.
The American Brain Tumor Association (ABTA) today announced the funding of $1.37 million towards 23 new research grants to advance brain tumor science and treatments, across all brain tumor types and ages. Dedicated to advancing the field of neuro-oncology and accelerating the discovery of life-saving treatments, the ABTA is proud to have invested more than $35 million, to approximately 700 researchers to support 800 projects, to date.
A champion of the brain tumor community for 50 years running, the American Brain Tumor Association (ABTA) has launched its most ambitious undertaking yet – a five-year, $50-million fundraising campaign called Meet Hope Head On.
The Meet Hope Head On campaign will focus on three pillars: tripling the ABTA’s research investment, doubling the number of patients served, and doubling federal funding for brain tumor research. Throughout its 50-year history, the ABTA has provided vital seed money to fund high-risk, high-reward research grants which have contributed to significant breakthroughs in treating brain tumors by many of the country’s leading researchers.
The American Brain Tumor Association (ABTA) today announced the funding of $821,000 towards 20 new research grants to advance brain tumor science and treatments. With more than $34 million invested in research to date, across all brain tumor types and ages, the ABTA research program plays a critical role in advancing the understanding of brain tumors and building the next generation of brain tumor researchers.
A first-of-its-kind, cross-sectional survey of patients, caregivers and physicians on the diagnosis and treatment of brain metastases, conducted by the American Brain Tumor Association (ABTA), as part of its Metastatic Brain Tumor Initiative, revealed disparities in practice patterns and communication around metastatic brain tumors. These data highlight the need to increase accessibility to clinical trials, establish clear standards of care and improve physician-patient communication reflective of the unique needs of patients with brain metastases (BM). The survey results have been published open access in the journal Neuro-Oncology Practice.
American Brain Tumor Association
8550 W. Bryn Mawr Ave. Ste 550
Chicago, IL 60631
